摘要
目的 :观察双歧杆菌联合标准四联疗法根治幽门螺杆菌(Helicobacter pylori,Hp)的临床疗效。方法 :将160例Hp阳性患者随机分为A、B组各80例。A组口服埃索美拉唑、胶体果胶铋、阿莫西林、克拉霉素;B组在A组基础上加服双歧杆菌活菌胶囊,共用药14 d。治疗结束后4周再次行^(13)C呼气检测Hp,比较各组的Hp根除率及不良反应发生率。结果 :A组Hp根除率91.8%,B组Hp根除率92.3%,两组Hp根除率无统计学差异;Ⅳ级不良反应发生率A组高于B组,其中腹泻、恶心、腹胀、口腔异味的发生率,A组明显高于B组,差异有统计学意义。结论 :双歧杆菌联合标准四联疗法未能提高Hp根除率,但明显提高治疗完成率和降低不良反应发生率。
Objective： To observe the clinical efficacy of Bifidobacterium combined with standard quadruple therapy in the treatment ofHelicobacterpylori （Hp） infection. Methods： One hundred and sixty cases of patients with Hp infection were randomly divided into group A and B with 80 cases each. All the patients were treated for 14 days with oral administration of esomeprazole, colloidal bismuth pectin, amoxicillin and clarithromycin and meanwhile the patients in group B were additionally given Bifidobacterium capsule. Hp infection was detected by ~3C exhalation test at 4 weeks after treatment. The eradication rate of Hp and the incidence of adverse reactions were compared between the two groups. Results： The comparison of eradication rate of Hp between group A and B showed no significant differences （91.8% vs 92.3%）. The incidence of grade IV adverse reactions was higher in group A than in group B, in which the incidence of diarrhea, nausea, abdominal distension and oral odor was significantly higher in group A than in group B （P〈0.05）. Conclusion： Bifidobacterium combined with standard quadruple therapy can not improve the eradication rate of Hp, but significantly improve the completion rate of the treatment and reduce the incidence of adverse reactions.
出处
《上海医药》
CAS
2017年第7期27-29,共3页
Shanghai Medical & Pharmaceutical Journal
基金
上海市卫计委资助课题(项目名称:益生菌对慢性萎缩性胃炎合并Hp感染患者的保护机制研究
项目编号:20154001)
关键词
幽门螺杆菌
四联疗法
双歧杆菌
Helicobacter pylori
quadruple therapy
Bifidobacterium
